ClinicalTrials.gg
CompletedNCT07478588EHMet-DIAUpdated Oct 8, 2026

Structured Physical Activity Intervention in Patients With MASLD Receiving a Mediterranean Diet

An interventional study of Exercise plus Mediterranean diet and At-home exercise plus Mediterranean diet in MASLD, sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla. Completed at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 9 months after the study started (first participant enrolled Jun 2022, registered Mar 2026).
Updated Oct 8, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Fatty Liver with a site in Spain — 11 open to participants now, 12 under way, 4 of them phase 3. Fatty Liver · Spain.

Enrollment
14th of 23
96 · median 165
Started
2022
with 1 other
No phase
12 of 28
1 open now
Registered
27th of 28
by date

Among the 28 studies in Fatty Liver with a site in Spain, this one is the 14th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2022, is one of 12 with no phase, and was the 27th registered.

Fatty Liver

666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

11 of the 28 studies in Fatty Liver with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Fatty Liver with a site in Spain, or all of them as a file.
02

Study summary

Lifestyle interventions based on diet and physical activity are the cornerstone of management for metabolic dysfunction-associated steatotic liver disease (MASLD), yet individual responses remain highly variable. Advanced imaging biomarkers and genetic profiling may help to characterize response patterns. This study aimed to evaluate the impact of a Mediterranean diet-based lifestyle intervention, with or without structured physical activity, on liver steatosis and fibrosis assessed by magnetic resonance imaging, and to identify determinants of treatment response.

Read the detailed description

This randomized controlled trial included adults with histologically confirmed metabolic dysfunction-associated steatotic liver disease (MASLD) recruited between June 2022 and February 2023 at two tertiary referral centres in Spain (Virgen del Rocío University Hospital, Seville, and University Hospital of Valladolid). Exclusion criteria included other causes of chronic liver disease, excessive alcohol intake (>20 g/day in women and >30 g/day in men) , inability to perform regular physical activity, current participation in other clinical trials, and use of steatogenic or investigational drugs.

At the screening visit, all patients received counselling to follow a Mediterranean diet enriched with extra virgin olive oil. Participants were then randomized 1:1 to a structured physical activity programme (exercise group) or to a control group receiving standard lifestyle recommendations during a 12-week active intervention period. Randomization was performed using a computer-generated sequence with concealed allocation. This was followed by a further 12-week observation phase without supervised intervention, with a total follow-up period of 24 weeks, designed to reflect real-life clinical practice.

The sample size was calculated based on the primary endpoint of steatosis improvement. Assuming an absolute difference of 30% between groups, with a two-sided α level of 0.05 and 80% power, a minimum of 36 patients per group was required. To account for an anticipated dropout rate of 20%, the target sample size was increased to 45 patients per group.

The study protocol was approved by the local ethics committees of both centres, and all participants provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.

03

Conditions studied

  • MASLD

Keywords

  • MASLD
  • Lifestyle intervention
  • Liver steatosis
  • MASH
  • Metabolic dysfuction-associated steatotic liver disease
  • Physical activity
  • Exercise
  • Mediterranean diet
  • Magnetic resonance imaging
  • Proton density fat fraction
  • Genetic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with confirmed metabolic dysfunction-associated steatotic liver disease (MASLD)

Exclusion criteria

Exclusion Criteria:

  • Other causes of chronic liver disease
  • Excessive alcohol intake (>20 g/day in women and >30 g/day in men)
  • Inability to perform regular physical activity
  • Current participation in other clinical trials
  • Use of steatogenic or drugs.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Exercise

    Supervised exercise programme consisting of moderate-intensity aerobic activity and resistance training three times per week at a sports centre.

    Behavioral: Exercise plus Mediterranean diet

  • Active comparator
    Control

    The control group was advised to perform moderate-intensity physical activity at home according to EASL recommendations

    Behavioral: At-home exercise plus Mediterranean diet

Interventions

  • BehavioralExercise plus Mediterranean diet

    Supervised exercise programme consisting of moderate-intensity aerobic activity and resistance training three times per week at a sports centre, plus counselling to follow a Mediterranean diet enriched with extra virgin olive oil.

  • BehavioralAt-home exercise plus Mediterranean diet

    Moderate-intensity physical activity at home according to EASL recommendations, plus counselling to follow a Mediterranean diet enriched with extra virgin olive oil.

06

What researchers measure

Primary outcomes

  1. Steatosis response

    Defined as a ≥30% reduction in MRI-proton density fat fraction (PDFF) from baseline to week 24

    Time frame: From baseline to week 24

  2. Fibrosis regression

    ≥20% reduction in liver stiffness measured by MRE or improvement of at least one fibrosis stage

    Time frame: Frome baseline to week 24

Secondary outcomes

  1. % Change in Weight

    Weight measured in kilograms

    Time frame: From baseline to week 24

  2. % Change in Waist Circumference

    Waist circumference measured in centimeters

    Time frame: From baseline to week 24

  3. % Change in Fat Mass

    Fat mass measured in % by impedanciometry

    Time frame: From baseline to week 24

  4. % Change in Muscle Mass

    Muscle mass measured in % by impedanciometry

    Time frame: From baseline to week 24

  5. % Change in Fasting Triglycerides

    Triglycerides measured in mg/dL in blood test

    Time frame: From baseline to week 24

  6. % Change in Fasting Aspartate Transaminase

    Aspartate transaminase measured in U/L in blood test

    Time frame: From baseline to week 24

  7. % Change in Fasting Alanine Transaminase

    Alanine transaminase measured in U/L in blood test

    Time frame: From baseline to week 24

  8. % Change in Fasting Glycosylated Haemoglobin

    Glycosylated haemoglobin measured in % in blood test

    Time frame: From baseline to week 24

  9. Change in Patient Reported Diet Habits by MEDAS Questionnaire

    Assessment of patient reported diet habits using the MEDAS questionnaire, a validated 14-item questionnaire of Mediterranean Diet adherence. Score lower than 9 means low adherence to Mediterranean Diet, and score equal or higher than 9 means good adherence to Mediterranean Diet.

    Time frame: From baseline to week 24

  10. Change in Patient Reported Diet Habits by Dietary Items Recount

    Assessment of patient reported diet habits using the Dietary Items Recount survey (units/week), that quantifies average consumption of specific foods or beverages over a seven-day period.

    Time frame: From baseline to week 24

  11. Change in Exercise Tolerance

    Assessment of exercise tolerance and functional capacity using the 6-minute walk test (6MWT). The 6MWT is a functional, submaximal exercise test that measures the maximum distance in meters a person can walk at fastest speed on a flat, hard surface in 6 minutes.

    Time frame: From baseline to week 24

  12. Change in Patient Reported Physical Activity

    Assessment of patient reported physical activity using the International Physical Activity Questionnaire (IPAQ) questionnaire. IPAQ classifies individuals into three categories based on their total Metabolic Equivalent of Task (MET) minutes per week. Low physical activity: Less than 600 MET-minutes/week; moderate physical activity: Between 600 and 3,000 MET-minutes/week; or high physical activity: More than 3,000 MET-minutes/week.

    Time frame: From baseline to week 24

  13. Change in Patient Reported Individual Functioning

    Assessment of individual functioning using the SF-12 questionnaire, a 12-item, patient-reported, validated questionnaire assessing Health-Related Quality of Life (HRQoL) across eight physical and mental domains. It covers physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health.

    Time frame: From baseline to week 24

  14. Change in Patient Reported Quality of Life

    Assessment of patient reported quality of life using the CLDQ-NAFLD Questionnaire, a 36-item, validated, disease-specific questionnaire that assesses patient reported outcomes over the past two weeks across six domains: abdominal symptoms, activity/energy, emotional health, fatigue, systemic symptoms, and worry.

    Time frame: From baseline to week 24

  15. Genetic Analysis

    Rate of patients (in %) carrying different polymorphisms. The genotyping of the single nucleotide polymorphisms (SNP) of interest, PNPLA3 rs738409, HSD17B13 rs72613567, TM6SF2 rs58542926, FUT2 rs601338, MBOAT7 rs641738 and GCKR rs1260326, was performed using TaqMan SNP genotyping assays and chemistries (ThermoFisher, USA).

    Time frame: At baseline

07

Study locations

2 sites
  • Hospital Universitario Virgen del Rocío de Sevilla
    Seville, Spain
  • Hospital Universitario de Valladolid
    Valladolid, Spain
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Sep 2023, 15 months.

Of 136 non-industry interventional studies with no phase under Fatty Liver, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 15 months is below that.

Counting every sponsor, half of 145 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Feb 2023 → Sep 2023 and completion Apr 2024 → Oct 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 17, 2026
StartActual
Jun 1, 2022
Primary completionActual
Sep 1, 2023was Feb 2023
CompletionActual
Oct 31, 2023was Apr 2024
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Feb 23, 2023→Sep 1, 2023
Oct 8, 2026
Study completion
Apr 3, 2024→Oct 31, 2023
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Primary completion Feb 23, 2023→Sep 1, 2023
    Study completion Apr 3, 2024→Oct 31, 2023

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07478588
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Jun 1, 2022
Primary completion
Sep 1, 2023
Completion
Oct 31, 2023
Last update
Oct 8, 2026

Study contacts

Manuel Romero-Gómez
principal investigator · Hospital Universitario Virgen del Rocío de Sevilla

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion